Qinghui Tang, Houjuan Zou, Caihong Guo
Aug 20, 2014
Citations
0
Influential Citations
21
Citations
Quality indicators
Journal
International journal of cardiology
Abstract
Warfarin is one of the most widely used oral anticoagulants, with a narrow therapeutic window and high inter-individual variability in the dose needed to achieve target INR [1–4]. It was reported that the gene CYP2C9 and VKORC1 polymorphisms in the population may affect the therapeutic warfarin dose requirement, which could increase the risk for over anticoagulation and hemorrhage complicat ions during warfar in treatment [1–3] . A number of pharmacogenetics-based algorithms integrating patients' demographic data and different genotypes have been established to predict the dose of warfarin [1,2,4–8]. Existing clinical trials [1,2,4–8] were performed to investigate the efficacy and safety of pharmacogeneticsguided warfarin dosing, but the results were controversial. Recently, the EU-PACT study reported that pharmacogenetics-based dosing of warfarin was better than standard dosing, with higher percentage of time in the therapeutic INR range (PTTR) than that of standard clinical during the initiation of warfarin therapy [1]. However, the COAG study failed to show the advantage of pharmacogenetics compared to conventional dosing procedures [2]. To further explore this, we performed the current meta-analysis to systematically investigate it. Subgroup and meta-regression analyses were used to study potential confounding factors. We searched the Pubmed, Embase and the Cochrane Library, using the